CD200 and laryngeal carcinoma: Our data indicate that also DC-based immunotherapy supported by the use of mAb anti-CD200 may be effective in the treatment of laryngeal cancer in future, but further studies analyzing the influence of both mAb anti-CD200 and anti-CD200R, and Mo-DC on autologous laryngeal cancer cell cultures are essential.